Tags

Type your tag names separated by a space and hit enter

False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report.
J Addict Med. 2022 Nov-Dec 01; 16(6):e417-e419.JA

Abstract

BACKGROUND

Labetalol hydrochloride (LH) is a pharmacologic treatment for hypertensive disease (HD) in pregnancy. However, for pregnant persons with substance use disorders (SUDs), LH may interfere with urine drug testing.

CASE SUMMARY

We present 3 pregnant or postpregnant persons with SUDs who experienced presumptive positive urine immunoassays for fentanyl while prescribed LH for perinatal HD.

DISCUSSION

Labetalol hydrochloride treatment for HD in pregnancy can result in presumptive positive urine immunoassays for fentanyl. Unrecognized or misinterpreted, this phenomenon can lead to significant consequences for pregnant and postpartum persons with co-occurring substance use and hypertensive disorders. Clinicians caring for pregnant persons with SUDs must be aware of this phenomenon and its sequelae when ordering and interpreting urine immunoassays for fentanyl.

Authors+Show Affiliations

From the Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA (AW); Wake Forest School of Medicine, Winston-Salem, NC (BCI); Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA (KS); College of Education, Oregon State University, Corvallis, OR (TAF).No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

35972891

Citation

Wanar, Amita, et al. "False-positive Fentanyl Urine Detection After Initiation of Labetalol Treatment for Hypertension in Pregnancy: a Case Report." Journal of Addiction Medicine, vol. 16, no. 6, 2022, pp. e417-e419.
Wanar A, Isley BC, Saia K, et al. False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report. J Addict Med. 2022;16(6):e417-e419.
Wanar, A., Isley, B. C., Saia, K., & Field, T. A. (2022). False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report. Journal of Addiction Medicine, 16(6), e417-e419. https://doi.org/10.1097/ADM.0000000000001010
Wanar A, et al. False-positive Fentanyl Urine Detection After Initiation of Labetalol Treatment for Hypertension in Pregnancy: a Case Report. J Addict Med. 2022 Nov-Dec 01;16(6):e417-e419. PubMed PMID: 35972891.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report. AU - Wanar,Amita, AU - Isley,Breanna Cassidy, AU - Saia,Kelley, AU - Field,Thomas A, Y1 - 2022/08/17/ PY - 2022/8/17/pubmed PY - 2022/11/19/medline PY - 2022/8/16/entrez SP - e417 EP - e419 JF - Journal of addiction medicine JO - J Addict Med VL - 16 IS - 6 N2 - BACKGROUND: Labetalol hydrochloride (LH) is a pharmacologic treatment for hypertensive disease (HD) in pregnancy. However, for pregnant persons with substance use disorders (SUDs), LH may interfere with urine drug testing. CASE SUMMARY: We present 3 pregnant or postpregnant persons with SUDs who experienced presumptive positive urine immunoassays for fentanyl while prescribed LH for perinatal HD. DISCUSSION: Labetalol hydrochloride treatment for HD in pregnancy can result in presumptive positive urine immunoassays for fentanyl. Unrecognized or misinterpreted, this phenomenon can lead to significant consequences for pregnant and postpartum persons with co-occurring substance use and hypertensive disorders. Clinicians caring for pregnant persons with SUDs must be aware of this phenomenon and its sequelae when ordering and interpreting urine immunoassays for fentanyl. SN - 1935-3227 UR - https://www.unboundmedicine.com/medline/citation/35972891/False-positive_Fentanyl_Urine_Detection_after_Initiation_of_Labetalol_Treatment_for_Hypertension_in_Pregnancy:_A_Case_Report. DB - PRIME DP - Unbound Medicine ER -